NCT06255912View on ClinicalTrials.gov

Clinical Trial for Advanced or Metastatic Pancreatic Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

March 1, 2029

Study Completion Date

March 1, 2031

Conditions
Pancreas Cancer
Interventions
DRUG

LTC004 + MIL-97

Dose group 1：MIL97:0.2mg/kg,Day1,Q3W,LTC004:90ug/kg,Day3,Q3W Dose group 2:MIL97:0.2mg/kg,Day1,Q3W,LTC004:180ug/kg,Day3,Q3W Dose group -1:MIL97:0.2mg/kg,Day1,Q3W,LTC004:45ug/kg,Day3,Q3W

DRUG

LTC004 + MIL-97+chemotherapy

LTC004 + MIL-97+chemotherapy

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER

NCT06255912 - Clinical Trial for Advanced or Metastatic Pancreatic Cancer | Biotech Hunter | Biotech Hunter